Ophthalmology Therapeutics Market to 2017

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) September 28, 2011 -- GBI Research has found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in markets such as glaucoma and allergic conjunctivitis. However, unmet need in the wet age macular degeneration and diabetic retinopathy markets make the ophthalmology market attractive despite generic erosion.

The attractiveness of the wet age macular degeneration and diabetic retinopathy markets is evident from the considerable amount of research and development (R&D) activity for these indications and the launch of promising molecules in the period 2010-2017. The major factor driving the growth of the market is the growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools and an increase in the prevalence of diabetes. The expiry of blockbuster drugs’ patents and increasing pressure from cheap off-label products in some markets will be the key market restraints.

The entry of generics will cause the glaucoma market share to shrink, leading to the growth of the wet age macular degeneration and diabetic retinopathy markets. The share of the market generated by allergic conjunctivitis therapies, which includes a considerable number of generics, will remain the same in 2017. Due to the extensive presence of generics in the market, allergic conjunctivitis companies will take steps to improve the revenue potential of their drugs. The Rx to OTC switch is one of the strategies that can be leveraged at the right time to increase revenue potential. In addition, strategies such as branded generics will be increasingly used in the ophthalmology market.

For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Ophthalmology-Therapeutics-Market-to-2017-Protein-Kinase-Inhibitors-and-Prostaglandin-H-Synthase-Inhibitors-to-Drive-Diabetic-Retinopathy-Market&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&CompanyID=fprco

GBI Research has found the global ophthalmology market to be facing changes such as low treatment seeking and diagnosis rates. This will result in huge untapped opportunities in the market.

GBI Research, the leading business intelligence provider, has released its latest research, “Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market”, which provides insights into the global ophthalmology therapeutics market forecast until 2017. The report provides an in-depth analysis of the six therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indication. In addition, the report includes insights into the ophthalmology R&D pipeline. GBI Research analysis shows that the overall global ophthalmology market for glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration was valued at $10.3 billion in 2010. The market is expected to grow at a CAGR of 3.6% for the forecast period to reach $13.2 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Ophthalmology-Therapeutics-Market-to-2017-Protein-Kinase-Inhibitors-and-Prostaglandin-H-Synthase-Inhibitors-to-Drive-Diabetic-Retinopathy-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&CompanyID=fprco

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

ophthalmology     Pharmaceuticals and Healthcare     therapeutics